4ET-1103

The rapid-fire pace of Eli Lilly's dealmaking continued Tuesday when the US pharma spent an undisclosed amount to acquire 4E Therapeutics and its pipeline of oral MNK inhibitors. The biotech is at least the second Lilly has bought with a focus on non-opioid pain solutions.4E's lead candidate is 4ET1103, which targets the MNK-eIF4E signalling pathway in peripheral sensory neurons. According to the company, MNK-mediated phosphorylation of eIF4E causes increased gene expression, which in turn amplifies pain signal creation. By inhibiting MNK, the asset is designed to stop the flow of peripherally generated pain signals to the brain, where pain perception occurs.The experimental treatment — the first MNK inhibitor developed specifically to treat pain to reach in-human studies — has completed a Phase I trial, demonstrating a "favourable" safety profile. "Seeing this science — years of research into the molecular events that cause pain to become chronic — advance from basic research to clinical development and now to Lilly's pipeline, provides excitement for the opportunity to accelerate new therapies to patients living with chronic pain," said Theodore Price, 4E co-founder, in a company release. He's also the director of the Center for Advanced Pain Studies at The University of Texas at Dallas.Padding the pain portfolioLilly's takeout of 4E comes about a year after it picked up SiteOne Therapeutics and its non-opioid pipeline — though with a different approach to treating pain than the latest acquisition.Through the buyout, Lilly gained SiteOne's lead candidate STC-004, a NaV1.8 sodium channel blocker similar to Vertex Pharmaceuticals' Journavx (suzetrigine), which last year became the first non-opioid pain treatment greenlit by the FDA in more than two decades (see – Spotlight On: Lilly could ride in Vertex's slipstream to put opioids in rear view mirror).Despite the historic approval, however, Vertex has struggled to break into chronic pain settings (see – Spotlight On: Despite setbacks, Vertex keeps its eyes on the chronic pain prize).And, up until Tuesday's deal, most players in the non-opioid space following Journavx's approval have also been operating in the sodium channel inhibitor space (see – Spotlight On: NaV-igating the next non-opioid agents for pain). With a differentiated mechanism — and now validation from Lilly — 4E's pain portfolio could inject new excitement into a disease area in need of refresh.M&A menagerieThe acquisition is also the latest example of Lilly casting a wide M&A net with its obesity cash for early and/or high risk assets. The drugmaker is currently the most active dealmaker in major pharma, having struck 12 deals in the first quarter alone. However, it is certainly not spending the most, with companies like Merck & Co., Sanofi and Novo Nordisk splashing out billions on comparatively late-stage assets as they face down nearer-term patent problems (see – Vital Signs: Eli Lilly's early-and-often deal strategy moves in on Kelonia).The addition of 4E adds pain to Lilly's areas of interest, joining developers of radiotherapy, gene therapy, RNAi, gene editing, molecular glues and vaccines who recently caught the pharma's eye (see – Spotlight On: Lilly dives deeper into prevention — five key takeaways).

Eli Lilly has acquired Texas-based 4E Therapeutics, Inc., as per a press release from 4E, adding the first clinical-stage MNK inhibitor developed for pain to its growing non-opioid pain portfolio. The deal expands Lilly’s neuroscience pipeline with a novel peripheral analgesic mechanism as the company increases investment in chronic pain indications. Financial deal terms were not disclosed. The transaction is structured as a full acquisition, conveying global rights to 4E Therapeutics’ pipeline of orally available MNK inhibitors by default, consistent with standard full-company buyout mechanics. Aquilo Partners LP served as exclusive financial advisor to 4E Therapeutics. 4E Therapeutics’ lead compound, 4ET1103, is the first MNK inhibitor developed specifically for pain to advance to human clinical trials, where it reported a favorable safety profile in a Phase I study. The compounds target the MNK-eIF4E signaling pathway in peripheral sensory neurons, phosphorylating eIF4E to modulate translation of pain-related proteins at the site of nociception. Preclinical studies have suggested that MNK-eIF4E signaling regulates the production of proteins involved in pain sensitization, making the pathway a potential target for chronic pain conditions. By acting peripherally rather than centrally, the mechanism is designed to deliver analgesia without the CNS-mediated side effects — including addiction risk and sedation — associated with opioids and many existing analgesics. The acquisition reinforces Lilly’s pattern of bolt-on neuroscience deals to access novel peripheral pain mechanisms. In May 2025, Lilly acquired SiteOne Therapeutics for up to USD 1 billion, adding STC-004, a Phase II-ready Nav1.8 inhibitor for chronic pain — a structurally comparable deal targeting a different peripheral ion channel. Lilly also holds a licensing agreement with Belgium-based Confo Therapeutics for CFTX-1554, an AT2R antagonist that entered Phase II in April 2026 for peripheral pain. Together, the deals give Lilly exposure to multiple non-opioid pain mechanisms, including MNK-eIF4E inhibition, Nav1.8 blockade, and AT2R antagonism. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.